MDD articles & resources on Made-in-China.com

Solos Endoscopy Gets ISO 13485:2003 Certification From TUV Sud America

Feb 7, 2014

Solos Endoscopy, a provider of healthcare instruments to hospitals across the US, announce that the company has received its ISO 13485:2003 Certification from TUV SUD America. The certification to ISO 13485:2003 will in turn allow Solos ...

Tags: TUV SUD, FDA, ISO Certified, MammoView

Patients with Depression Have Areas of Reduced Cortical Thickness

Jan 23, 2014

Patients with depression have areas of reduced cortical thickness, with clear distinctions between those with bipolar disorder and major depressive disorder (MDD), report US researchers. "Cortical thickness may prove to be a useful tool ...

Tags: Health, Medicine

Patients with MDD Increased Use of Maladaptive and Decreased Use of Adaptive ER Strategies

Jan 16, 2014

By Lucy Piper, Senior medwireNews Reporter Patients with bipolar disorder and major depressive disorder (MDD) have increased use of maladaptive and decreased use of adaptive emotion regulation (ER) strategies, researchers report. ...

Tags: emotion regulation, Larissa Wolkenstein, University of Tübingen

Mylan Has Obtained FDA Approval for sANDA for GSK's WELLBUTRIN XL

Aug 26, 2013

Mylan has obtained FDA approval for its supplemental abbreviated new drug application (sANDA) for the generic version of GSK's WELLBUTRIN XL, bupropion hydrochloride extended-release tablets USP (XL), 300mg. Bioequivalence study results ...

Tags: FDA Approval, drug application

Integrity Applications Has Received CE Mark for Glucotrack DF-F Non-Invasive Device

Jun 7, 2013

Integrity Applications, an Israel-based medical device company, has received CE Mark approval for its GlucoTrack DF-F non-invasive device. The GlucoTrack DF-F is a glucose measuring device that uses a patented combination of ultrasound, ...

Tags: DF-F Device, Integrity Applications

Mylan Has Been Sued Jointly by Pfizer,Wyeth Pharmaceutical,Wyeth LLC and PF Prism

Dec 7, 2012

Mylan has been sued jointly by Pfizer,Wyeth Pharmaceutical,Wyeth LLC and PF Prism regarding the filing of an abbreviated new drug application (ANDA) with the US food and drug administration (FDA) for desvenlafaxine succinate ...

Tags: Mylan, desvenlafaxine succinate extended-release tablets, MDD

H. Lundbeck Have Submitted a New Drug Application

Dec 5, 2012

Takeda Pharmaceutical Company and H. Lundbeck have submitted a new drug application (NDA) to the FDA for vortioxetine (Lu AA21004), an investigational drug for the treatment of major depressive disorder (MDD). Vortioxetine is under ...

Tags: Takeda Pharmaceutical Company, major depressive disorder, MDD

Edgemont Pharmaceuticals Launched a Formulation Dose of Bupropion Extended-Release Tablets

Nov 29, 2012

Edgemont Pharmaceuticals has launched a new formulation dose of bupropion extended-release tablets in a strength of 450mg dose. The Forfivo XL, which the company claims, is the only available 450mg dose of an extended-release bupropion ...

Tags: bupropion extended-release tablets, bupropion product

MDD

Related Products